News
Current news and announcements from Amyloidosis Switzerland
World Amyloidosis Day 2026 – participants wanted for a roundtable
August 30, 2026
World Amyloidosis Day takes place on October 26, 2026. For this year’s edition a roundtable discussion is being recorded that focuses on the role of family members and caregivers in amyloidosis. The Amyloidosis Alliance is still looking for participants.
- Wanted: a person affected by amyloidosis together with a family member or caregiver
- Topic: the role of the caregiver and how the disease affects their relationship and everyday life together
- Both participants need a very good command of English
- The Amyloidosis Alliance arranges flights and hotel and covers the costs
Schedule and contact
Arrival on September 17, 2026, recording of the roundtable on the morning of September 18, 2026 in Paris, return journey afterwards. The discussion will be broadcast on World Amyloidosis Day, October 26, 2026. If you are interested, please contact the Amyloidosis Alliance directly.
Amyloidosis information event in Lucerne – November 14, 2026
July 21, 2026
We warmly invite you to the «Amyloidosis» information event, taking place on Saturday, November 14, 2026, from 9:30 AM to 12:00 PM at Lucerne Cantonal Hospital. From 8:45 AM we welcome you with coffee and croissants.
- Talks by leading specialists on cardiac amyloidosis, current and future therapies, and cardiac imaging
- Exercise with amyloidosis and being well supported through therapy
- Followed by light refreshments and a personal exchange with the speakers at Restaurant Feingut
- Free of charge and wheelchair accessible – one accompanying person per patient is welcome
Registration required – deadline October 30, 2026
Saturday, November 14, 2026, 9:30 AM – 12:00 PM
Patient meeting in Davos – October 16, 2026
July 21, 2026
We at the Amyloidose-Schweiz association warmly invite you to the patient meeting at the Hochgebirgsklinik in Davos. Thanks to PD Dr. David Niederseer and his team, we are able to hold our meeting there. All types of amyloidosis (ATTR-CM, AL, ATTR-PN and all subtypes) are included.
- Sharing information and experiences among those affected
- Answering questions about amyloidosis and personal concerns
- Latest findings on therapy as well as amyloidosis and exercise
- Free of charge and no membership required – accompanying persons welcome
Registration required – deadline October 8, 2026
Friday, October 16, 2026, 2:00 PM – 4:00 PM
AL amyloidosis information meeting in Vienna – October 6, 2026
July 20, 2026
The association «Leben mit Amyloidose – Amyloidosis Austria» and Multiple Myeloma Self-Help Austria invite patients and relatives to an information meeting: «News on diagnosis, treatment and living with AL amyloidosis». The event is also live streamed – online participation is possible.
- News on diagnosis and treatment – Priv.-Doz. Dr.in Hermine Agis (AKH / Medical University of Vienna)
- Presentation of the webinar «Living with amyloidosis – What is good for me?» – Mag. Dennis Johnson
- Duration approx. 3 hours, followed by a Q&A and exchange of experiences over drinks and snacks
- Participation on site in Vienna or online
Registration
Tuesday, October 6, 2026, 4:00 PM – 7:00 PM
Patient Meeting in Zurich – September 4, 2026
May 17, 2026
Amyloidosis Switzerland cordially invites you to a patient meeting in Zurich. This meeting provides an opportunity to exchange information among people affected by all types of amyloidosis (ATTR-CM, AL, ATTR-PN and all subtypes).
- Exchange of information and experiences among affected individuals
- Answers to questions about amyloidosis and personal concerns
- Latest therapeutic findings
- Free of charge and no membership required – companions welcome
Registration required – by August 24, 2026
Friday, September 4, 2026, 2:00 PM – 4:00 PM
AMVUTTRA® (Vutrisiran) reimbursed by Swiss health insurance from 1 April 2026
March 1, 2026
From 1 April 2026, AMVUTTRA® (Vutrisiran) is newly reimbursable for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
BEYONTTRA® (Acoramidis) reimbursed by Swiss health insurance from 1 March 2026
February 1, 2026
From 1 March 2026, BEYONTTRA® (Acoramidis) is newly reimbursable for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Peer to Peer - Affected coaching Affected
January 24, 2025
Martin Bürgi, certified myPeer Coach
Through support at eye level, as an expert from experience, I would like to provide motivating guidance to find a way to deal well with being affected.
- Resource and solution-oriented
- Clear yet flexible
- Open to new ways and ideas
As someone affected by amyloidosis myself, I know the challenges and questions that arise when receiving the diagnosis. I would like to accompany those affected and their relatives in orienting themselves in everyday life after receiving the diagnosis. Support them in finding a path that helps them deal with these challenges.
For this reason, I was able to train as a certified myPeer Coach at the myPeer Association in 2025.